Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of hyperopia, when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
LASIK has become one of the most common refractive eye procedures performed in the country. In the hyperopia procedure, a steepening occurs on the corneal surface, rather than the flattening procedure (myopic treatment). The surgeon will produce a standard keratomileusis flap using a microkeratome, exposing the corneal stroma. Recontouring under the flap is then accomplished by the removal of tissue from the stroma with the laser. This recontouring results in an altering of effective lens power of the central cornea, measured in diopters (D). The MEL 80 Excimer Laser System will be evaluated for its ability to create accurate and stable hyperopic refractive correction results.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment of Hyperopic LASIK | Other | Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MEL 80 Hyperopic LASIK Treatment | Device | Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D. |
|
| Measure | Description | Time Frame |
|---|---|---|
| At the point of stability, a minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome. | Point of stability | |
| A minimum of 85% of eyes targeted for emmetropia should have an uncorrected visual acuity of 20/40 or better at the postoperative interval at which stability has been established. | Point of stability | |
| A minimum of 95% of eyes should have a change of < 1.00 D in manifest refraction spherical equivalent (MRSE) between 2 refractions performed at least 3 months apart, and the mean rate of MRSE change per month should be < 0.04 D. | Point of stability | |
| 75% of eyes undergoing astigmatic treatment should be within ± 1.00 D of the attempted astigmatism correction by the point of stability. | Point of stability | |
| Distance BSCVA of worse than 20/40 at the postoperative interval at which stability has been established should occur in less than 1.0% of eyes that had a BSCVA of 20/20 or better before surgery. | Point of stability | |
| Loss of more than 2 lines of BSCVA should occur in less than 5.0% of eyes. | Point of stability | |
| Less than 5% of eyes treated for sphere only should have a magnitude of postoperative manifest refractive astigmatism that varies from baseline cylinder by greater than 2.00 D at the postoperative interval at which stability has been established. | Point of stability | |
| Incidence of Adverse Events to occur in less 1% of eyes |
| Measure | Description | Time Frame |
|---|---|---|
| Subject Satisfaction: As measured by a subjective questionnaire, and will be considered as a secondary efficacy variable. | Postoperative visits 3, 6, 9, 12, 18 and 24 months | |
| Incidence of Complications | Postoperative visits |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Steven Dell, MD | Texan Eye Care | Principal Investigator |
| John Doane, MD | Discover Vision Centers | Principal Investigator |
| Richard Hoffman, MD | Fine, Hoffman, and Packer LLC | Principal Investigator |
| Howard Fine, MD | Fine, Hoffman, and Packer LLC | Principal Investigator |
| Mark Packer, MD | FIne, Hoffman, and Packer LLC | Principal Investigator |
| David Tanzer, MD | US Navy Refractive Surgery Center, San Diego, CA | Principal Investigator |
| Steve Schallhorn, MD | US Navy Refractive Surgery Center, San Diego, CA | Principal Investigator |
| John Vukich, MD | Davis Duehr Dean Eye Clinic | Principal Investigator |
| Jon Dishler, MD | Dishler Laser Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| US Navy Refractive Surgery Center | San Diego | California | 92106 | United States | ||
| Dishler Laser Institute |
Not provided
| ID | Term |
|---|---|
| D006956 | Hyperopia |
| ID | Term |
|---|---|
| D012030 | Refractive Errors |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Postoperative visits |
| Patient Symptoms: As measured by a subjective questionnaire, will be considered as a secondary safety variable. | Preoperative and Postoperative visits 3, 6, 9, 12, 18 and 24 months |
| Greenwood Village |
| Colorado |
| 80111 |
| United States |
| Discover Vision Centers | Kansas City | Missouri | 64055 | United States |
| Fine, Hoffman, and Packer | Eugene | Oregon | 97401 | United States |
| Texan Eye Care | Austin | Texas | 78746 | United States |
| Davis Duehr Dean Eye Clinic | Madison | Wisconsin | 53717 | United States |